The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

DHAQ     1,4-dihydroxy-5,8-bis[2-(2...

Synonyms: Mitozantrone, mitoxantrone, NSC-279836, NSC-287836, NSC-299195, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Novantron


Psychiatry related information on Novantron


High impact information on Novantron


Chemical compound and disease context of Novantron


Biological context of Novantron


Anatomical context of Novantron


Associations of Novantron with other chemical compounds


Gene context of Novantron


Analytical, diagnostic and therapeutic context of Novantron


  1. Selective alopecia with mitoxantrone. Arlin, Z.A., Friedland, M.L., Atamer, M.A. N. Engl. J. Med. (1984) [Pubmed]
  2. Intensive single-agent mitoxantrone for metastatic breast cancer. Shpall, E.J., Jones, R.B., Holland, J.F., Bhardwaj, S., Paciucci, P.A., Wilfinger, C.L., Strashun, A. J. Natl. Cancer Inst. (1988) [Pubmed]
  3. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. Leteurtre, F., Kohlhagen, G., Paull, K.D., Pommier, Y. J. Natl. Cancer Inst. (1994) [Pubmed]
  4. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. Ross, D.D., Yang, W., Abruzzo, L.V., Dalton, W.S., Schneider, E., Lage, H., Dietel, M., Greenberger, L., Cole, S.P., Doyle, L.A. J. Natl. Cancer Inst. (1999) [Pubmed]
  5. Mitoxantrone trial in multiple sclerosis. Chaudhuri, A., Behan, P.O. Lancet (2003) [Pubmed]
  6. Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. Ogilvie, G.K., Moore, A.S., Obradovich, J.E., Elmslie, R.E., Vail, D.M., Straw, R.C., Salmon, M.D., Klein, M.K., Atwater, S.W., Ciekot, P.E. J. Am. Vet. Med. Assoc. (1993) [Pubmed]
  7. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. Clavio, M., Garrone, A., Pierri, I., Michelis, G.L., Balocco, M., Albarello, A., Varaldo, R., Canepa, P., Miglino, M., Ballerini, F., Canepa, L., Gobbi, M. Oncol. Rep. (2005) [Pubmed]
  8. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status. Ostberg, A., Pittas, F., Taylor, B. Internal medicine journal. (2005) [Pubmed]
  9. Intraperitoneal chemotherapy with mitoxanthrone in ovarian cancer. Le Donne, M., Messina, G., Buda, C., Corrado, F., Pettineo, G., Salimbeni, V., Irato, S. Tumori. (1997) [Pubmed]
  10. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S.L., Galle, P.R., Stremmel, W., Oren, M., Krammer, P.H. J. Exp. Med. (1998) [Pubmed]
  11. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Jonker, J.W., Smit, J.W., Brinkhuis, R.F., Maliepaard, M., Beijnen, J.H., Schellens, J.H., Schinkel, A.H. J. Natl. Cancer Inst. (2000) [Pubmed]
  12. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. Abbott, D.W., Freeman, M.L., Holt, J.T. J. Natl. Cancer Inst. (1998) [Pubmed]
  13. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. Cowan, J.D., Neidhart, J., McClure, S., Coltman, C.A., Gumbart, C., Martino, S., Hutchins, L.F., Stephens, R.L., Vaughan, C.B., Osborne, C.K. J. Natl. Cancer Inst. (1991) [Pubmed]
  14. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Weiss, R.B., Rifkin, R.M., Stewart, F.M., Theriault, R.L., Williams, L.A., Herman, A.A., Beveridge, R.A. Lancet (2000) [Pubmed]
  15. A multidrug resistance transporter from human MCF-7 breast cancer cells. Doyle, L.A., Yang, W., Abruzzo, L.V., Krogmann, T., Gao, Y., Rishi, A.K., Ross, D.D. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  16. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Asnafi, V., Buzyn, A., Thomas, X., Huguet, F., Vey, N., Boiron, J.M., Reman, O., Cayuela, J.M., Lheritier, V., Vernant, J.P., Fiere, D., Macintyre, E., Dombret, H. Blood (2005) [Pubmed]
  17. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Hiddemann, W., Kreutzmann, H., Straif, K., Ludwig, W.D., Mertelsmann, R., Donhuijsen-Ant, R., Lengfelder, E., Arlin, Z., Büchner, T. Blood (1987) [Pubmed]
  18. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Bellosillo, B., Villamor, N., Colomer, D., Pons, G., Montserrat, E., Gil, J. Blood (1999) [Pubmed]
  19. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Zhou, S., Morris, J.J., Barnes, Y., Lan, L., Schuetz, J.D., Sorrentino, B.P. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  20. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Bhalla, K., Ibrado, A.M., Tourkina, E., Tang, C., Grant, S., Bullock, G., Huang, Y., Ponnathpur, V., Mahoney, M.E. Blood (1993) [Pubmed]
  21. Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia. Nitta, M., Kato, Y., Strife, A., Wachter, M., Fried, J., Perez, A., Jhanwar, S., Duigou-Osterndorf, R., Chaganti, R.S., Clarkson, B. Blood (1985) [Pubmed]
  22. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Ross, D.D., Karp, J.E., Chen, T.T., Doyle, L.A. Blood (2000) [Pubmed]
  23. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Moore, J.O., Dodge, R.K., Amrein, P.C., Kolitz, J., Lee, E.J., Powell, B., Godfrey, S., Robert, F., Schiffer, C.A. Blood (1997) [Pubmed]
  24. Ligation of the CD44 adhesion molecule inhibits drug-induced apoptosis in human myeloid leukemia cells. Allouche, M., Charrad, R.S., Bettaieb, A., Greenland, C., Grignon, C., Smadja-Joffe, F. Blood (2000) [Pubmed]
  25. Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Canal, P., Attal, M., Chatelut, E., Guichard, S., Huguet, F., Muller, C., Schlaifer, D., Laurent, G., Houin, G., Bugat, R. Cancer Res. (1993) [Pubmed]
  26. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Harker, W.G., Slade, D.L., Dalton, W.S., Meltzer, P.S., Trent, J.M. Cancer Res. (1989) [Pubmed]
  27. Therapy of molecular relapse in acute promyelocytic leukemia. Lo Coco, F., Diverio, D., Avvisati, G., Petti, M.C., Meloni, G., Pogliani, E.M., Biondi, A., Rossi, G., Carlo-Stella, C., Selleri, C., Martino, B., Specchia, G., Mandelli, F. Blood (1999) [Pubmed]
  28. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Stasi, R., Del Poeta, G., Venditti, A., Masi, M., Stipa, E., Dentamaro, T., Cox, C., Dallapiccola, B., Papa, G. Blood (1994) [Pubmed]
  29. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Wulf, G.G., Wang, R.Y., Kuehnle, I., Weidner, D., Marini, F., Brenner, M.K., Andreeff, M., Goodell, M.A. Blood (2001) [Pubmed]
  30. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Diah, S.K., Smitherman, P.K., Aldridge, J., Volk, E.L., Schneider, E., Townsend, A.J., Morrow, C.S. Cancer Res. (2001) [Pubmed]
  31. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cisternino, S., Mercier, C., Bourasset, F., Roux, F., Scherrmann, J.M. Cancer Res. (2004) [Pubmed]
  32. Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Boonstra, R., Timmer-Bosscha, H., van Echten-Arends, J., van der Kolk, D.M., van den Berg, A., de Jong, B., Tew, K.D., Poppema, S., de Vries, E.G. Br. J. Cancer (2004) [Pubmed]
  33. c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells. Stadheim, T.A., Kucera, G.L. Leuk. Res. (2002) [Pubmed]
  34. Therapeutic role of mitoxantrone in multiple sclerosis. Neuhaus, O., Kieseier, B.C., Hartung, H.P. Pharmacol. Ther. (2006) [Pubmed]
  35. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Harris, A.L., Cantwell, B.M., Carmichael, J., Wilson, R., Farndon, J., Dawes, P., Ghani, S., Evans, R.G. Lancet (1990) [Pubmed]
  36. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Hartung, H.P., Gonsette, R., König, N., Kwiecinski, H., Guseo, A., Morrissey, S.P., Krapf, H., Zwingers, T. Lancet (2002) [Pubmed]
  37. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Adlakha-Hutcheon, G., Bally, M.B., Shew, C.R., Madden, T.D. Nat. Biotechnol. (1999) [Pubmed]
WikiGenes - Universities